Imaging, Diagnosis, Prognosis EDNRB and DCC Salivary Rinse Hypermethylation Has a Similar Performance as Expert Clinical Examination in Discrimination of Oral Cancer/Dysplasia versus Benign Lesions

Purpose: Promoter hypermethylation has been recently proposed as a means for head and neck squamous cell carcinoma (HNSCC) detection in salivary rinses. In a prospective study of a high-risk population, we showed that endothelin receptor type B (EDNRB) promoter methylation in salivary rinses is a useful biomarker for oral cancer and premalignancy. Experimental Design: Using that cohort, we evaluated EDNRB methylation status and 8 additional genes. Clinical risk assessment by expert clinicians was conducted and compared with biomarker performance in the prediction of premalignant andmalignant disease. Methylation status of 9 genes was analyzed in salivary rinses of 191 patients by quantitative methylation-specific PCR. Results:HOXA9,EDNRB, and deleted in colorectal cancer (DCC)methylationwere associated (P1⁄40.012;P < 0.0001; P 1⁄4 0.0005) with premalignant or malignant disease. On multivariable modeling, histological diagnosis was only independently associated with EDNRB (P1⁄4 0.0003) orDCC (P1⁄4 0.004)methylation. A subset of patients received clinical risk classification (CRC)by expert clinicians basedon lesion examination. CRC, DCC, and EDNRB were associated with diagnosis of dysplasia/cancer on univariate (P 1⁄4 0.008; P 1⁄4 0.026; P 1⁄4 0.046) and multivariate analysis (P 1⁄4 0.012; P 1⁄4 0.037; P 1⁄4 0.047). CRC identified dysplasia/ cancer with 56% of sensitivity and 66% of specificity with a similar area under curve [AUC; 0.61, 95% confidence interval (CI)1⁄40.60–0.81]when compared toEDNRB andDCC combinedAUC(0.60, 95%CI1⁄4 0.51–0.69), sensitivity of 46% and specificity of 72%. A combination of EDNRB, DCC, and CRC was optimal AUC (0.67, 95% CI 1⁄4 0.58–0.76). Conclusions: EDNRB and/or DCC methylation in salivary rinses compares well to examination by an expert clinician in CRC of oral lesions. These salivary biomarkers may be particularly useful in oral premalignancy andmalignancy screening in clinical care settings inwhich expert clinicians are not available. Clin Cancer Res; 19(12); 3268–75. 2013 AACR.